Haemonetics Corporation (HAE): Projected Sales Volume

Haemonetics Corporation dominates plasma processing technologies, generating protected revenue from the supply of consumables. The company's target sales level reflects market expectations, where the parameter has stabilized at 3.72. The standardization of medical centers around HAE equipment ensures consistent demand for components, while strict FDA certifications and patents block new entrants from entering the blood filtration segment.

HAE - Haemonetics Company Company Revenue Forecast over the range 07/04/2022 - 11/15/2026

Metric breakdowns and analytics for Haemonetics Corp. (HAE)

- stock value and consensus price forecast:

Price Chart Haemonetics Corp|HAE - Consensus Target

- stock exchange capitalization data:

Market Capitalization Haemonetics Corp|HAE - Total Enterprise Value

- book capitalization information:

Book Value per Share Haemonetics|HAE - Accounting Capitalization|Market Capitalization to Book Value Ratio haemonetics.com|HAE - Company Total Asset Base

- debt level and financial liquidity data:

- earnings and market ratios statistics:

HAE - Company Net Income|Expected Profit Haemonetics Corporation|HAE - Market Cap to Net Income Ratio|Projected Price to Earnings Haemonetics Corp|HAE - PEG Multiple|EV/EBITDA Multiple Haemonetics Corporation|HAE - Operating income before deduction of amortization|Earnings per share for the last twelve months Haemonetics|HAE - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months haemonetics.com|HAE - Net earnings per share growth this year|Earnings growth forecast for next year Haemonetics Corporation

- sales revenue and business income indicators:

HAE - Company Total Revenue|Company Projected Revenue Haemonetics Corp.|HAE - Market Cap to Revenue Ratio|Forward Price-to-Revenue Multiple Haemonetics Corp|HAE - Revenue Change YoY (Last 12 Months)

Comprehensive company analysis:HAE Haemonetics

The stable assembly of hematological equipment at Haemonetics Corporation (HAE), supported by supplier diversification, is reflected in the company's planned sales dynamics. This indicator synthesizes the market consensus across reports, measuring the probability of revenue retention as a reliability filter; its decline signals a risk of shrinking margin coverage and the potential for forced liquidation of investor positions.

Competing companies